Alpha Wasserman Proteomic Technologies Announces an Agreement to Jointly Develop Methodologies in Collaboration with PBI
News Dec 08, 2006
Alfa Wassermann Proteomic Technologies, LLC,(AWPT) has announced an agreement with Pressure BioSciences, Inc, to jointly develop sample preparation methodologies that enrich for low abundance proteins and sub cellular organelles from cells and tissues.
AWPT will utilize PBI’s Pressure Cycling Technology (PCT) to enhance techniques for cell disruption, specifically for the preparation of samples prior to downstream processing with the AW Promatix 1000™.
PBI’s Pressure Cycling Technology Sample Preparation System (PCT SPS) can allow precisely controlled and reproducible cell disruption from a wide variety of cells and tissues. The AW Promatix 1000™ is capable of automated fractionation of organelles and sub-cellular moieties.
To this end, the AW Promatix 1000™ can provide enriched fractions of organelles and sub-cellular particles, thereby delivering more abundance proteins and making thorough proteome studies and first-time discoveries a possibility.
The collaboration between AWPT and low PBI looks to combine PBI’s PCT SPS with the AW Promatix 1000 in an effort to provide the research community with a sample preparation and processing method with significantly enhanced capabilities when compared to currently used techniques.
Dino DiCamillo, President of Alfa Wassermann Proteomic Technologies, said: “Our initial success with the Pressure BioSciences’s PCT SPS led AWPT to formalize an agreement. Our intent is to develop tissue disruption methods to better enable users of the AW Promatix 1000™ across a number of relevant tissue and cell types. Our technology coupled with effective sample preparation will lead to improved fractionation, isolation, and enrichment of organelles and low abundance proteins. We are very excited to enter this phase of our relationship.”
Richard T. Schumacher, President and CEO of Pressure BioSciences, commented: “This collaboration extends our research and development focus on the reproducible and precise extraction of biomolecules with alternating high and low hydrostatic pressure. The ability to fractionate subcellular complexes using AWPT’s technology enhanced by the consistent and tightly controlled cell disruption by PCT SPS should help researchers better understand cellular regulation and function, which in turn may lead to the discovery of better drugs against such devastating illnesses as infectious, oncologic (cancer), neurodegenerative, and heart diseases.”
Some MRSA infections could be tackled using widely-available antibiotics, suggests new research. A team of scientists used genome sequencing technology to identify which genes make MRSA susceptible to a previously defined combination of drugs. They identified a number of mutations centered around a protein known as a penicillin-binding protein 2a or PBP2a.